Patent Expert: It's Not Over For Gilead, Still Has Strong Defense Against Merck
March 24, 2016 at 15:20 PM EDT
In a new report, Citi analyst Robyn Karnauskas discusses the Gilead Sciences, Inc. (NASDAQ: GILD)/Merck & Co., Inc. (NYSE: MRK) ...